Imagine Owning Epizyme (NASDAQ:EPZM) And Wondering If The 46% Share Price Slide Is Justified

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn’t blame long term Epizyme, Inc. (NASDAQ:EPZM) shareholders for doubting their decision to hold, with the stock down 46% over a half decade. Even worse, it’s down 11% in about a month, which isn’t fun at all.

See our latest analysis for Epizyme

Epizyme isn’t currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn’t make profits, we’d generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over half a decade Epizyme reduced its trailing twelve month revenue by 47% for each year. That puts it in an unattractive cohort, to put it mildly. On the face of it we’d posit the share price fall of 12% compound, over five years is well justified by the fundamental deterioration. This loss means the stock shareholders are probably pretty annoyed. It is possible for businesses to bounce back but as Buffett says, ‘turnarounds seldom turn’.

Depicted in the graphic below, you’ll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGS:EPZM Income Statement, May 6th 2019
NasdaqGS:EPZM Income Statement, May 6th 2019

If you are thinking of buying or selling Epizyme stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

While the broader market gained around 11% in the last year, Epizyme shareholders lost 12%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year’s performance caps off a bad run, with the shareholders facing a total loss of 12% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

Of course Epizyme may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.